AWP
PACB icon

Ascent Wealth Partners’s Pacific Biosciences PACB Stock Holding History

Ascent Wealth Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,000
Closed -$58K – 112
2015
Q2 		$58K Buy
+10,000
New +$57.9K 0.03% 115

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Ascent Wealth Partners's PACB Position: Q3 2015 in Review

Ascent Wealth Partners sold out of Pacific Biosciences (PACB) in Q3 2015, closing a stake of 10,000 shares — an estimated $58K sold.

Ascent Wealth Partners first reported a position in PACB in Q2 2015 and held it in 1 quarter. The position peaked at $58K in Q2 2015. 90 funds tracked by Wall St. Rank hold PACB as of Q3 2015.

  • Ascent Wealth Partners reported no remaining Pacific Biosciences position as of Q3 2015 after selling out during the quarter.
  • Ascent Wealth Partners sold 10,000 Pacific Biosciences shares in Q3 2015, an estimated $58K.
  • Ascent Wealth Partners first reported a position in Pacific Biosciences in Q2 2015 and held it in 1 quarter.
  • Ascent Wealth Partners's Pacific Biosciences position peaked at $58K in Q2 2015.
  • 90 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2015.

Based on Ascent Wealth Partners's 13F filing for Q3 2015, filed 21 Aug 2019.